Bright Technologies Fund Invests in APR Applied Pharma Research

APR Applied Pharma Research SA (APR), headquartered in Balerna, develops and licenses innovative, value added and patented healthcare products and proprietary drug delivery systems primarily in the oral and topical fields; APR also invests in companies or early stage innovative projects and provides a balanced mix of equity funding and/or financing together with APR’s development, scientific, technical, marketing, licensing and management skills and know how; finally, APR supports biotech and pharmaceutical companies in the development of new pharmaceutical projects by providing on a contract basis added value, consultancy and R&D services under contract using a General Contractor approach.

Bright Technologies Fund invests an undisclosed amount in APR. The fund’s advisor, Enrico Braglia, will become a member of the Board of Directors of APR.

„We are pleased to invest in APR. This investment underlines our commitment to Swiss life science, a sector with incredible growth potential“, said Enrico Braglia, CEO at Onelife Advisors SA advisor to Bright Technologies Fund. The fund aligns its investment in high-tech companies with significant market potential and supports start-up from beginning.

„The investment of Bright Technologies Fund into APR is part of our overall strategic plan for the growth, which foresees the expansion of the firm’s geographic presence into the fast-growing markets as well as the acceleration of our development programs. Among recent accomplishments, we entered in a licensing partnership with Norgine BV for the EU and selected non-EU markets. We expanded into Latin America and Russia, where we have signed License and Supply Agreements with undisclosed leading pharmaceutical companies. We also expect to finalize our partnering efforts in China, shortly“, said APR CEO and founder Paolo Galfetti „I am excited about the opportunity to work with Enrico Braglia who will bring to APR his extensive expertise and network in the pharmaceutical industry.“